Posts by: Janet Stewart, MSc

Janet Stewart, MSc

Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.

January 4, 2018

Eisai and Biogen to Continue Phase 2 Alzheimer’s Therapy Trial for Six More Months

News

Eisai and Biogen had hoped that using an advanced statistical method to analyze Phase 2 clinical trial results would show at 12 months rather than the normal 18 that their Alzheimer’s therapy ... Read more

December 18, 2017December 18, 2017

Higher Educational Linked to Lower Alzheimer’s Risk in Study Looking at Gene Variants

News

Certain variations found in genes that correlate with intelligence and may affect “cognitive reserve” are evident in people with higher levels of education and appear to work to protect against Alzheimer’s ... Read more

October 26, 2017

Biogen and Eisai Agree to Work Together on Alzheimer’s Therapy Aducanumab

News

Biogen and Eisai have deepened their partnership by agreeing to work together on the continued development of the Alzheimer’s therapy aducanumab (BIIB037), which targets harmful beta amyloid protein clusters. The U.S. ... Read more

October 24, 2017

Alzheimer’s Research Team Wins $25 Million to Help It Compete for 2018 XPRIZE

News

The founders of Edelman Financial Services have donated $25 million to a group called the Alzheimer’s Disease Team to help it compete for a global XPRIZE. Jean and Ric Edelman announced ... Read more

September 26, 2017September 26, 2017

Targeting ApoE in Brain Alone May Lead to Alzheimer’s Treatment, Researchers Say

News

Scientists are coming closer to understanding how the gene variant apolipoprotein E4 (ApoE4) raises the risk of Alzheimer’s disease. Blocking ApoE4 — one of several variants of the ApoE gene — ... Read more

August 10, 2017August 10, 2017

Alzheimer’s Patients Using Antidepressants at Higher Risk of Head Injuries, Study Finds

News

The use of antidepressants in patients with Alzheimer’s disease increased their risk of head injuries, a Finnish study recently found. The risk of head injuries in these patients previously had ... Read more

July 14, 2017July 14, 2017

E-Scape Bio Hits $63 Million in Financing to Develop Alzheimer’s Therapy

News

E-Scape Bio, the Gladstone Institutes’ spin-off company working to develop therapies for neurodegenerative disorders such as Alzheimer’s disease, announced that it has raised a total of $63 million in Series A financing ... Read more

July 13, 2017

2017 Alzheimer Award Goes to Shi-Jiang Li for Developing CARE Index

News

Prof. Shi-Jiang Li, PhD, is the recipient of the 2017 Alzheimer Award granted every year by the associate editors of the Journal of Alzheimer’s Disease (JAD). Li was singled out ... Read more